Gabapentin Drug Market Report

Gabapentin Drug Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Feb 12, 2020
  • PAGES：152
  • REPORT CODE：GMM469590
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Gabapentin Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.3% during the forecast period.

    This report presents the market size and development trends by detailing the Gabapentin Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Gabapentin Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Gabapentin Drug industry and will help you to build a panoramic view of the industrial development.

    Gabapentin Drug Market, By Type:

    • Capsule

    • Tablet

    • Oral solution

    Gabapentin Drug Market, By Application:

    • Postherpetic neuralgia in adults

    • Partial onset seizures

    • Others

    Some of the leading players are as follows:

    • InvaGen Pharmaceuticals

    • Mylan

    • Teva

    • Epic Pharma

    • CSPC Ouyi Pharmaceutical

    • Taro

    • ACI HealthCare Limited

    • Glenmark

    • Alkem Laboratories

    • Tris Pharma

    • Pfizer

    • Acella Pharmaceuticals

    • Aurobindo Pharma

    • Zydus Pharmaceuticals

    • Jiangsu Hengrui Medicine

    • Amneal Pharmaceuticals

    • Sun Pharmaceutical

    • Depomed

    • Hi-Tech Pharmaceuticals

    • Lupin Limited

    • Apotex

    • Sciegen Pharmaceuticals

    • Marksans Pharma

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Gabapentin Drug Market: Technology Type Analysis

    • 4.1 Gabapentin Drug Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Gabapentin Drug Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Capsule

      • 4.3.2 Tablet

      • 4.3.3 Oral solution

    5 Gabapentin Drug Market: Product Analysis

    • 5.1 Gabapentin Drug Product Market Share Analysis, 2018 & 2026

    • 5.2 Gabapentin Drug Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Gabapentin Drug Market: Application Analysis

    • 6.1 Gabapentin Drug Application Market Share Analysis, 2018 & 2026

    • 6.2 Gabapentin Drug Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 Postherpetic neuralgia in adults

      • 6.3.2 Partial onset seizures

      • 6.3.3 Others

    7 Gabapentin Drug Market: Regional Analysis

    • 7.1 Gabapentin Drug Regional Market Share Analysis, 2018 & 2026

    • 7.2 Gabapentin Drug Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 InvaGen Pharmaceuticals

      • 9.1.1 InvaGen Pharmaceuticals Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Mylan

      • 9.2.1 Mylan Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Teva

      • 9.3.1 Teva Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Epic Pharma

      • 9.4.1 Epic Pharma Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 CSPC Ouyi Pharmaceutical

      • 9.5.1 CSPC Ouyi Pharmaceutical Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Taro

      • 9.6.1 Taro Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 ACI HealthCare Limited

      • 9.7.1 ACI HealthCare Limited Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 Glenmark

      • 9.8.1 Glenmark Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Alkem Laboratories

      • 9.9.1 Alkem Laboratories Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 Tris Pharma

      • 9.10.1 Tris Pharma Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 Pfizer

      • 9.11.1 Pfizer Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Acella Pharmaceuticals

      • 9.12.1 Acella Pharmaceuticals Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Aurobindo Pharma

      • 9.13.1 Aurobindo Pharma Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 Zydus Pharmaceuticals

      • 9.14.1 Zydus Pharmaceuticals Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 Jiangsu Hengrui Medicine

      • 9.15.1 Jiangsu Hengrui Medicine Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 Amneal Pharmaceuticals

      • 9.16.1 Amneal Pharmaceuticals Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 Sun Pharmaceutical

      • 9.17.1 Sun Pharmaceutical Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

    • 9.18 Depomed

      • 9.18.1 Depomed Company overview

      • 9.18.2 Financial performance

      • 9.18.3 Product benchmarking

      • 9.18.4 Strategic initiatives

      • 9.18.5 SWOT analysis

    • 9.19 Hi-Tech Pharmaceuticals

      • 9.19.1 Hi-Tech Pharmaceuticals Company overview

      • 9.19.2 Financial performance

      • 9.19.3 Product benchmarking

      • 9.19.4 Strategic initiatives

      • 9.19.5 SWOT analysis

    • 9.20 Lupin Limited

      • 9.20.1 Lupin Limited Company overview

      • 9.20.2 Financial performance

      • 9.20.3 Product benchmarking

      • 9.20.4 Strategic initiatives

      • 9.20.5 SWOT analysis

    • 9.21 Apotex

      • 9.21.1 Apotex Company overview

      • 9.21.2 Financial performance

      • 9.21.3 Product benchmarking

      • 9.21.4 Strategic initiatives

      • 9.21.5 SWOT analysis

    • 9.22 Sciegen Pharmaceuticals

      • 9.22.1 Sciegen Pharmaceuticals Company overview

      • 9.22.2 Financial performance

      • 9.22.3 Product benchmarking

      • 9.22.4 Strategic initiatives

      • 9.22.5 SWOT analysis

    • 9.23 Marksans Pharma

      • 9.23.1 Marksans Pharma Company overview

      • 9.23.2 Financial performance

      • 9.23.3 Product benchmarking

      • 9.23.4 Strategic initiatives

      • 9.23.5 SWOT analysis

     

    The List of Tables and Figures (Totals 91 Figures and 158 Tables)

    • Figure Capsule Gabapentin Drug market, 2015 - 2026 (USD Million)

    • Figure Tablet Gabapentin Drug market, 2015 - 2026 (USD Million)

    • Figure Oral solution Gabapentin Drug market, 2015 - 2026 (USD Million)

    • Figure Postherpetic neuralgia in adults market, 2015 - 2026 (USD Million)

    • Figure Partial onset seizures market, 2015 - 2026 (USD Million)

    • Figure Others market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Gabapentin Drug market, by country, 2015 - 2026 (USD Million)

    • Table North America Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table North America Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table North America Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Canada Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Canada Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Europe Gabapentin Drug market, by country, 2015 - 2026 (USD Million)

    • Table Europe Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Europe Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Europe Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Germany Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Germany Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table France Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table France Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Italy Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Italy Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Spain Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Spain Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Gabapentin Drug market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table China Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table China Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Japan Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Japan Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table India Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table India Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Gabapentin Drug market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table MEA Gabapentin Drug market, by country, 2015 - 2026 (USD Million)

    • Table MEA Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table MEA Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table MEA Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Gabapentin Drug market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Gabapentin Drug market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Gabapentin Drug market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table InvaGen Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Mylan Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Teva Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Epic Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table CSPC Ouyi Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Taro Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table ACI HealthCare Limited Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Glenmark Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Alkem Laboratories Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Tris Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Acella Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Aurobindo Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Zydus Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Jiangsu Hengrui Medicine Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Amneal Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Sun Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Depomed Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Hi-Tech Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Lupin Limited Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Apotex Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Sciegen Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Marksans Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US